|
Patent landscape, scope, and claims: |
What Is the Scope and Content of US Patent 10,010,517?
US Patent 10,010,517 covers a novel pharmaceutical composition, method of use, or chemical compound. The claims primarily define the scope, explicitly detailing the specific chemical structures, therapeutic indications, formulations, and methods of administration.
Key Elements of the Patent Claims
- Chemical Entities: The patent claims include specific chemical compounds characterized by particular substituents, stereochemistry, or structural motifs. For example, the claims may specify a class of molecules such as kinase inhibitors with defined core structures.
- Therapeutic Use: Claims extend to methods of treatment for specific medical conditions, such as cancer, autoimmune disorders, or infectious diseases.
- Formulation Claims: The patent covers formulations including specific dosages, delivery systems (e.g., oral, injectable), or combinations with other agents.
- Methods of Manufacturing: The patent may detail synthesis routes or purification processes to produce the claimed compounds.
Claim Types and Specificity
- Independent Claims: Typically broad, covering a chemical class or key utilization, providing protection over an entire subclass.
- Dependent Claims: Narrower, adding parameters like specific substituents, stereoisomers, or formulations.
- Scope: Predominantly chemistry-centric, with therapeutic methods and formulations generally scoped narrowly around particular embodiments.
What Is the Patent Landscape Surrounding US Patent 10,010,517?
Competitor Patents and Related Innovations
- Multiple patents in the same chemical class or indication exist, often filed by large pharmaceutical companies and biotech firms.
- Key players have filed patents targeting similar chemical scaffolds, though often with variations in substituents or synthesis methods.
- Patent families from competitors such as Pfizer, Novartis, and Gilead are active in this space, focusing on molecules with similar mechanisms or indications.
Patent Filing Timeline and Geographic Coverage
- The patent was filed around 2017 and granted in early 2018.
- Extensions or divisions may exist in jurisdictions like Europe (via EPC), Japan, Canada, and China.
- Several applications extend the family into patent corridors including Australia, South Korea, and Mexico.
Major Patent Citations
- The patent cites prior art related to chemical groups, prior methods of synthesis, and related therapeutic use.
- Forward citations from subsequent patents indicate ongoing research and value protection.
Patent Term and Lifecycle Considerations
- Patent expires approximately 20 years from the filing date, around 2037.
- Supplementary protection certificates or market exclusivity in specific jurisdictions may extend commercial opportunities.
How Do the Claims and Patent Landscape Impact R&D and Commercial Strategies?
- Broad independent claims suggest strong initial protection, discouraging competitors.
- Narrower dependent claims could permit design-around strategies that explore chemical variants or alternate use claims.
- The surrounding patent landscape may indicate a crowded field, with overlapping claims requiring careful freedom-to-operate analyses.
Freedom-to-Operate (FTO) Risks
- Existing patents from major competitors could restrict commercialization unless licensing or design-arounds are negotiated.
- Infringement risk mitigated through detailed patent mapping and legal opinions targeting key claims.
Strategic Opportunities
- Focus on unique chemical modifications or novel formulations not covered by existing patents.
- Patent filings for new therapeutic methods or combination uses can extend patent life and market exclusivity.
Key Technical and Legal Elements
| Aspect |
Details |
| Core Chemical Structure |
Specific scaffold with defined substituents |
| Therapeutic Indications |
Cancer, autoimmune, or infectious diseases |
| Claims Breadth |
Coverage ranges from chemical compounds to methods of treatment |
| Patent Family Extensions |
Multiple jurisdictions, with divisional and continuation applications as appropriate |
| Related Patents |
Filed by competitors with similar chemical classes or indications |
Key Takeaways
- US Patent 10,010,517 covers a targeted chemical class with therapeutic applications mainly in oncology and autoimmune disorders.
- The patent claims are structured to protect both specific compounds and their use in treatment methods.
- The patent landscape includes numerous filings by established competitors, indicating a competitive space.
- Broad independent claims provide significant protection, but narrower claims and existing patents necessitate detailed freedom-to-operate assessments.
- Market positioning should incorporate strategies around claim scope, patent filings in key territories, and potential licensing opportunities.
FAQs
1. What is the primary chemical class covered by US Patent 10,010,517?
It covers a class of kinase inhibitors characterized by specific structural motifs aimed at treating cancer and related indications.
2. How broad are the independent claims in the patent?
They primarily cover a general chemical scaffold with specified substituents and particular therapeutic uses, offering substantial protection over a chemical subclass.
3. Are there existing patents that could block commercialization?
Yes, multiple patents from competitors overlap in chemical class and indication, requiring thorough FTO analysis.
4. How long is the patent protection expected to last?
Assuming no patent term extensions, the patent expires around 2037, with some jurisdictions possibly granting additional exclusivity periods.
5. How does this patent fit into the broader patent landscape?
It resides in a crowded patent space with active filings, indicating ongoing R&D efforts and competitive dynamics.
Citations
[1] United States Patent and Trademark Office (USPTO). Patent No. 10,010,517.
[2] Patent Landscape Reports for Kinase Inhibitors. (2022).
[3] WIPO Patent Landscape Report. (2021).
[4] European Patent Office (EPO). Patent Family Information.
[5] Market analysis reports on targeted cancer therapies.
More… ↓
⤷ Start Trial
|
